NOVA:FRA
Novo Nordisk A/S
35,94 €
arrow_downward
−0,22%(−0,080) 1D
6. stu, 22:00:00 GMT+1 · EUR
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za NOVA...
Otvori
35,60 €
Najviša
36,20 €
Najniža
35,60 €
Trž. kap.
138,20 mlr.
Prosj. kol.
762,00
Količina
310,00
52-tjed. najviša
54,80 €
52-tjed. najniža
30,45 €
Broj djelatnika
67 tis.
Otvori
35,60 €
Najviša
36,20 €
Najniža
35,60 €
Trž. kap.
138,20 mlr.
Prosj. kol.
762,00
Količina
310,00
52-tjed. najviša
54,80 €
52-tjed. najniža
30,45 €
Broj djelatnika
67 tis.
Vijesti
Iz web-izvora i od partnera za vijesti
Fierce Biotech
·
prije 23 sata
Chutes & Ladders—Novo's longtime CFO to hang up gloves as Galderma exec steps in
Seeking Alpha
·
prije 1 dan
Novo Nordisk Owns The Oral Weight Loss Market At 7.8x Operating Income (NYSE:NVO)
Morningstar
·
prije 2 dana
Novo Nordisk: What We Think of the Stock After Earnings
U.S. News - Money
·
prije 2 dana
European Shares Jump Over 1% After Democrats Sweep US Congress, Novo Nordisk Surges
Profil
Novo Nordisk A/S, doing business as Novo, is a Danish multinational pharmaceutical company. Novo manufactures and markets pharmaceutical products and services, primarily obesity and diabetes medications and devices. The corporation was created in 1989, through a merger of two Danish pharmaceutical companies, which date back to the 1920s.
Novo employs approximately 69,500 people in 80 countries, and markets its products in approximately 170 countries. Novo is controlled by majority shareholder Novo Holdings which holds 28% of its shares and a majority of its voting shares.
Novo is a full member of the European Federation of Pharmaceutical Industries and Associations.
The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo was named the most sustainable company in the world by the business magazine Corporate Knights. It is a leader in the FTSE4Good Index, and the only European company in the top ten.
Novo is the largest pharmaceutical company in Denmark. In 2023, Novo's market capitalization exceeded the GDP of Denmark, and it became the highest valued company in Europe. Wikipedia
Novo Nordisk A/S – informacije
Glavni izvršni direktorMike Doustdar
Zaposlenici66,7 tis.
Osnovano1923
SjedišteBagsværd, Hovedstaden, Danska
SektorHealth Care
Djelatnost-
Web-lokacijanovonordisk.com